CLYM
Climb Bio, Inc.
$10.55
-3.30%
$604.1M
No data for this timeframe.
Vol
Market Cap$604.1M
Cap SizeSmall Cap
Analyst ConsensusStrong Buy (95%)
Inst. Holders6 funds
Inst. Value$9.6M
Inst. Activity2 buys / 1 sells
Insider Activity0B / 4S
Insider Net $-$879.4K
SEC Reports8
Press Releases1
Recent Activity
Jun 5, 2026
SEC
Climb Bio announced translational pharmacometric modeling and initial Phase 1 safety data for CLYM116, its anti-APRIL mo
8-K — Impact 4/10
Jun 5, 2026
other
Climb Bio Presents CLYM116 Initial Phase 1 Safety Data and Translational Modeling Results at European Renal Association (ERA) Congress 2026 Supporting Continued Development
<p align="center"><em>Company to share additional CLYM116 clinical data and plans for further develo
May 29, 2026
SEC
Climb Bio filed an S-3 registration statement to register 11,587,000 shares of common stock for resale by selling stockh
S-3 — Impact 4/10
May 7, 2026
SEC
Climb Bio reported Q1 2026 EPS of -$0.20, beating consensus of -$0.26 by 23%, and reduced net loss to $13.7M from $20.8M
8-K — Impact 6/10
Apr 29, 2026
Insider
RA CAPITAL MANAGEMENT, L.P. sold 2,106,000 shares
Director @ $9.50 ($20.0M)
Feb 26, 2026
Insider
Thomas Stephen Basil sold 16,313 shares
Director @ $7.01 ($114.3K)
Feb 25, 2026
Insider
Thomas Stephen Basil sold 33,687 shares
Director @ $7.00 ($236.0K)
Inst.
TWO SIGMA INVESTMENTS, LP — DOUBLED
566,712 shares ($2.3M)
Price Targets
$19.77
+87.4% upside
Strong Buy
Current $10.55
Low $15.00
Median $19.00
High $26.00
13 analysts
$15.00
$26.00
Analyst Ratings
9Strong Buy
10Buy
1Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 12, 2026 | HC Wainwright & Co. | MAINTAIN | Buy → Buy |
| May 8, 2026 | Wedbush | MAINTAIN | Outperform → Outperform |
| May 6, 2026 | BTIG | MAINTAIN | Buy → Buy |
| May 5, 2026 | Chardan Capital | INITIATE | Buy |
| Apr 21, 2026 | Oppenheimer | MAINTAIN | Outperform → Outperform |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.22 ▲ +19.4% | $-0.27 — $-0.18 | 8 | |
| Current FY | $-0.87 ▲ +22.9% | $-0.98 — $-0.70 | 1% YoY | 8 |
| Next FY | $-1.12 ▲ +20.8% | $-1.44 — $-0.85 | -29% YoY | 9 |
| Next Q | $-0.21 ▲ +23.0% | $-0.26 — $-0.16 | -11% YoY | 8 |
Latest Reports
NEUTRAL
8-K
4/10
Climb Bio announced translational pharmacometric modeling and initial Phase 1 safety data for CLYM116, its anti-APRIL mo
Jun 5, 2026
NEUTRAL
S-3
4/10
Climb Bio filed an S-3 registration statement to register 11,587,000 shares of common stock for resale by selling stockh
May 29, 2026
NEUTRAL
Press
5/10
Climb Bio reported Q4 and full-year 2025 financial results, highlighting a cash position of $160.7 million with runway i
Mar 5, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD GROUP INC | $5.4M | — |
| TWO SIGMA INVESTMENTS, LP | $2.3M | DOUBLED |
| RENAISSANCE TECHNOLOGIES LLC | $1.3M | TRIM |
| MORGAN STANLEY | $594.2K | ADD |
| FMR LLC | $25.4K | DOUBLED |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Apr 29, 2026 | RA CAPITAL | A | $20.0M |
| Feb 26, 2026 | Thomas Stephen | SELL | $114.3K |
| Feb 25, 2026 | Thomas Stephen | SELL | $236.0K |
| Feb 13, 2026 | Thomas Stephen | SELL | $58.1K |
| Feb 12, 2026 | Thomas Stephen | SELL | $471.0K |
6 institutional holders with $9.6M total value (2,387,766 shares) as of 2025-Q4. Top holders: VANGUARD, TWO, RENAISSANCE. Net buying activity: 2 institutions added/increased vs 1 reduced.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 1,340,504 | $5.4M | 56.1% | — |
| 2 | TWO SIGMA INVESTMENTS, LP | 566,712 | $2.3M | 23.7% | DOUBLED +402.9% |
| 3 | RENAISSANCE TECHNOLOGIES LLC | 320,600 | $1.3M | 13.4% | TRIM -40.3% |
| 4 | MORGAN STANLEY | 148,538 | $594.2K | 6.2% | ADD +72.1% |
| 5 | FMR LLC | 6,349 | $25.4K | 0.3% | DOUBLED +187.8% |
| 6 | BANK OF AMERICA CORP /DE/ | 5,063 | $20.3K | 0.2% | NEAR_EXIT -79.5% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| TWO SIGMA INVESTMENTS, LP | DOUBLED | 112,681 | 566,712 | +402.9% | $2.3M | 2025-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | TRIM | 537,100 | 320,600 | -40.3% | $1.3M | 2025-Q4 |
| MORGAN STANLEY | ADD | 86,334 | 148,538 | +72.1% | $594.2K | 2025-Q4 |
| TWO SIGMA INVESTMENTS, LP | TRIM | 179,591 | 112,681 | -37.3% | $226.5K | 2025-Q3 |
| TWO SIGMA INVESTMENTS, LP | TRIM | 255,114 | 179,591 | -29.6% | $222.7K | 2025-Q2 |
| MORGAN STANLEY | TRIM | 176,979 | 99,459 | -43.8% | $123.3K | 2025-Q2 |
| BANK OF AMERICA CORP /DE/ | NEAR_EXIT | 37,287 | 7,627 | -79.5% | $9.5K | 2025-Q2 |
| FMR LLC | DOUBLED | 2,650 | 7,627 | +187.8% | $9.5K | 2025-Q2 |
| WELLS FARGO & COMPANY/MN | NEAR_EXIT | 17,449 | 244 | -98.6% | $303.00 | 2025-Q2 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | EXIT | 70,093 | 0 | -100.0% | $0.00 | 2025-Q2 |
| RENAISSANCE TECHNOLOGIES LLC | ADD | 372,300 | 514,398 | +38.2% | $627.6K | 2025-Q1 |
| FMR LLC | NEAR_EXIT | 13,563 | 2,650 | -80.5% | $3.2K | 2025-Q1 |
| UBS Group AG | DOUBLED | 16,247 | 415,355 | +2456.5% | $747.6K | 2024-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | DOUBLED | 68,600 | 372,300 | +442.7% | $670.1K | 2024-Q4 |
| MORGAN STANLEY | DOUBLED | 78,181 | 226,850 | +190.2% | $408.3K | 2024-Q4 |
| CITADEL ADVISORS LLC | NEW | — | 66,472 | — | $119.7K | 2024-Q4 |
| WELLS FARGO & COMPANY/MN | ADD | 13,248 | 17,062 | +28.8% | $30.7K | 2024-Q4 |
| MORGAN STANLEY | DOUBLED | 9,883 | 78,181 | +691.1% | $397.9K | 2024-Q3 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | NEW | — | 70,093 | — | $356.8K | 2024-Q3 |
2 unique insiders with 4 transactions. Net insider value: -$879.4K ($0.00 bought, $879.4K sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Apr 29, 2026 | RA CAPITAL MANAGEMENT, L.P. | Director | A | 2,106,000 | $9.50 | $20.0M |
| Feb 26, 2026 | Thomas Stephen Basil | Director | SELL | 16,313 | $7.01 | $114.3K |
| Feb 25, 2026 | Thomas Stephen Basil | Director | SELL | 33,687 | $7.00 | $236.0K |
| Feb 13, 2026 | Thomas Stephen Basil | Director | SELL | 10,000 | $5.81 | $58.1K |
| Feb 12, 2026 | Thomas Stephen Basil | Director | SELL | 90,000 | $5.23 | $471.0K |
8 SEC filing reports analyzed. Sentiment: 1 bullish, 1 bearish, 0 mixed, 6 neutral. Avg impact: 4.5/10.
NEUTRAL
8-K
4/10
Climb Bio announced translational pharmacometric modeling and initial Phase 1 safety data for CLYM11
Jun 5, 2026
NEUTRAL
S-3
4/10
Climb Bio filed an S-3 registration statement to register 11,587,000 shares of common stock for resa
May 29, 2026
BULLISH
8-K
6/10
Climb Bio reported Q1 2026 EPS of -$0.20, beating consensus of -$0.26 by 23%, and reduced net loss t
May 7, 2026
NEUTRAL
8-K
4/10
Climb Bio hosted an R&D Spotlight event on May 5, 2026, presenting positive topline data for its sub
May 5, 2026
BEARISH
8-K
7/10
Climb Bio entered into a securities purchase agreement for a $110.0 million private placement, selli
Apr 28, 2026
NEUTRAL
DEFA14A
3/10
Climb Bio, Inc. filed a definitive proxy statement (DEFA14A) for its 2026 annual meeting, proposing
Apr 24, 2026
NEUTRAL
8-K
3/10
Cindy Driscoll, Senior Vice President, Finance and principal accounting officer at Climb Bio, will d
Apr 3, 2026
NEUTRAL
8-K
5/10
Climb Bio reported financial results for Q4 and full year 2025, highlighting a cash position of $160
Mar 5, 2026
Current analyst consensus: Strong Buy (95% buy). Based on 20 analysts: 9 strong buy, 10 buy, 1 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$19.77 mean target
+87.4% upside
Strong Buy (1.07)
$15.00 Low
$26.00 High
| Metric | Value |
|---|---|
| Current Price | $10.55 |
| Target Low | $15.00 |
| Target Mean | $19.77 |
| Target Median | $19.00 |
| Target High | $26.00 |
| # Analysts | 13 |
| Recommendation | Strong Buy (1.07) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.22 | $-0.27 | $-0.18 | — | +19.4% | 5↑ 0↓ | $0.0B | 0.0% | 8 |
| Current FY 2026-12-31 |
$-0.87 | $-0.98 | $-0.70 | 1.4% | +22.9% | 5↑ 0↓ | $0.0B | 0.0% | 8 |
| Next FY 2027-12-31 |
$-1.12 | $-1.44 | $-0.85 | -29.4% | +20.8% | 4↑ 2↓ | $0.0B | 0.0% | 9 |
| Next Q 2026-09-30 |
$-0.21 | $-0.26 | $-0.16 | -11.2% | +23.0% | 5↑ 0↓ | $0.0B | 0.0% | 8 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.217 | |
| 7d ago | $-0.217 | |
| 30d ago | $-0.270 | +0.053 |
| 60d ago | $-0.276 | +0.058 |
| 90d ago | $-0.270 | +0.053 |
13 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 12 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 12, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| May 8, 2026 | Wedbush | MAINTAIN | Outperform | Outperform |
| May 6, 2026 | BTIG | MAINTAIN | Buy | Buy |
| May 5, 2026 | Chardan Capital | INITIATE | — | Buy |
| Apr 21, 2026 | Oppenheimer | MAINTAIN | Outperform | Outperform |
| Apr 15, 2026 | Mizuho | INITIATE | — | Outperform |
| Apr 8, 2026 | BTIG | REITERATE | Buy | Buy |
| Mar 24, 2026 | B. Riley Securities | INITIATE | — | Buy |
| Mar 18, 2026 | Truist Securities | INITIATE | — | Buy |
| Mar 11, 2026 | Raymond James | INITIATE | — | Strong Buy |
| Mar 10, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Mar 6, 2026 | Wedbush | MAINTAIN | Outperform | Outperform |
| Mar 6, 2026 | Baird | MAINTAIN | Outperform | Outperform |
| Mar 5, 2026 | Wedbush | INITIATE | — | Outperform |
| Feb 13, 2026 | Piper Sandler | INITIATE | — | Overweight |
| Dec 30, 2025 | Freedom Broker | INITIATE | — | Buy |
| Dec 18, 2025 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Oct 16, 2025 | William Blair | INITIATE | — | Outperform |
| Oct 16, 2025 | BTIG | REITERATE | Buy | Buy |
| Oct 13, 2025 | HC Wainwright & Co. | INITIATE | — | Buy |
| Sep 30, 2025 | BTIG | MAINTAIN | Buy | Buy |
| Sep 22, 2025 | BTIG | REITERATE | Buy | Buy |
| Aug 15, 2025 | Baird | INITIATE | — | Outperform |
| Jun 6, 2025 | Oppenheimer | INITIATE | — | Outperform |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 9 | 10 | 1 | 0 | 0 | 95% | |
| May 1, 2026 | 9 | 9 | 1 | 0 | 0 | 95% | |
| Apr 1, 2026 | 9 | 8 | 1 | 0 | 0 | 94% | |
| Mar 1, 2026 | 7 | 6 | 1 | 0 | 0 | 93% | |
| Feb 1, 2026 | 7 | 5 | 1 | 0 | 0 | 92% | |
| Jan 1, 2026 | 7 | 5 | 1 | 0 | 0 | 92% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
Jun 5, 2026
other
Climb Bio Presents CLYM116 Initial Phase 1 Safety Data and Translational Modeling Results at European Renal Association (ERA) Congress 2026 Supporting Continued Development
<p align="center"><em>Company to share additional CLYM116 clinical data and plans for further development at R&D Spotlight in late summer</em></p>
Jun 4, 2026
short_volume
Short Volume: CLYM — 59.4% short (0.4M / 0.6M)
Short: 352,104 | Exempt: 0 | TRF Vol: 592,816 | Short Ratio: 59.4% | Off-exchange volume (dark pool + OTC)
Jun 3, 2026
short_volume
Short Volume: CLYM — 61.1% short (0.3M / 0.5M)
Short: 311,917 | Exempt: 0 | TRF Vol: 510,140 | Short Ratio: 61.1% | Off-exchange volume (dark pool + OTC)
Jun 2, 2026
short_volume
Short Volume: CLYM — 68.5% short (0.5M / 0.7M)
Short: 506,283 | Exempt: 0 | TRF Vol: 738,911 | Short Ratio: 68.5% | Off-exchange volume (dark pool + OTC)
Apr 29, 2026
short_volume
Short Volume: CLYM — 65.5% short (0.4M / 0.7M)
Short: 432,746 | Exempt: 0 | TRF Vol: 660,639 | Short Ratio: 65.5% | Off-exchange volume (dark pool + OTC)
Apr 28, 2026
offering
Climb Bio, Inc. Announces $110.0 Million Private Placement
<p align="left">WELLESLEY HILLS, Mass., April 28, 2026 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical-stage biotechnology company de
Apr 8, 2026
routine
Climb Bio to Host R&D Spotlight Webcast Highlighting Budoprutug and the CD19 Opportunity on May 5, 2026
<p>WELLESLEY HILLS, Mass., April 08, 2026 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical-stage biotechnology company developing ther
Mar 9, 2026
earnings_calendar
CLYM Q4 2025 Earnings After Market Close — 2026-03-09
Mar 5, 2026
earnings
Climb Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates
<p align="center"><em>Dosing completed in Phase 1 study of budoprutug subcutaneous formulation, with data expected in H1 2026</em></p>
Feb 17, 2026
short_interest
FTD: CLYM — 94,056 shares ($0.5M) failed to deliver
Settlement: 20260217, Price: $5.67, FTD Value: $533,297.52, CLIMB BIO, INC. COMMON STOCK